ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco

GlobeNewswire

01/09

ALK (ALKB:DC / OMX: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to give a company presentation at the 44^th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, 15 January 2026, at 9.45 AM PST / 12.45 PM EST / 6.45 PM CET.

Representatives of the company will be available for meetings at the conference.

ALK-Abelló A/S

For further information, please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Maiken Riise Andersen, tel. +45 5054 1434

Business Development: Rasmus Just, tel. +45 4171 8431

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

InvestorNews_08January26_JP Morgan Global Healthcare Conference

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2602391930"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602391930\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602391930?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 00:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602391930","market":"sh","top_or_hot":-1,"title":"ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco","media":"GlobeNewswire","content":"<html><body><p>ALK (<i>ALKB:DC / OMX: ALK B</i>) today announced that the company’s president &amp; CEO, Peter Halling, is scheduled to give a company presentation at the 44<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco on <b>Thursday, 15 January 2026, at 9.45 AM PST / 12.45 PM EST / 6.45 PM CET.</b></p> <p>Representatives of the company will be available for meetings at the conference.</p> <p><b>ALK-Abelló A/S</b></p> <p><b>For further information, please contact:</b></p> <p><em>Investor Relations</em>: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525</p> <p><i>Media</i>: Maiken Riise Andersen, tel. +45 5054 1434</p> <p><i>Business Development</i>: Rasmus Just, tel. +45 4171 8431</p> <p><b><i>About ALK</i></b><br/><i>ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at </i><i>www.alk.net</i><i>.</i></p> <p>\n<strong>Attachment</strong>\n</p>\n<ul>\n<li>\nInvestorNews_08January26_JP Morgan Global Healthcare Conference\n</li>\n</ul>\n<br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml-eu.globenewswire.com/media/ZTJiOTBiMWUtZjBmMC00NjU3LThiMDYtZDVhZWY1MGQ1NGQ0LTEwMTM4MDQtMjAyNi0wMS0wOC1lbg==/tiny/ALK-Abello.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2026-01-09 00:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>ALK (<i>ALKB:DC / OMX: ALK B</i>) today announced that the company’s president &amp; CEO, Peter Halling, is scheduled to give a company presentation at the 44<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco on <b>Thursday, 15 January 2026, at 9.45 AM PST / 12.45 PM EST / 6.45 PM CET.</b></p> <p>Representatives of the company will be available for meetings at the conference.</p> <p><b>ALK-Abelló A/S</b></p> <p><b>For further information, please contact:</b></p> <p><em>Investor Relations</em>: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525</p> <p><i>Media</i>: Maiken Riise Andersen, tel. +45 5054 1434</p> <p><i>Business Development</i>: Rasmus Just, tel. +45 4171 8431</p> <p><b><i>About ALK</i></b><br/><i>ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at </i><i>www.alk.net</i><i>.</i></p> <p>\n<strong>Attachment</strong>\n</p>\n<ul>\n<li>\nInvestorNews_08January26_JP Morgan Global Healthcare Conference\n</li>\n</ul>\n<br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml-eu.globenewswire.com/media/ZTJiOTBiMWUtZjBmMC00NjU3LThiMDYtZDVhZWY1MGQ1NGQ0LTEwMTM4MDQtMjAyNi0wMS0wOC1lbg==/tiny/ALK-Abello.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2089283258.USD","symbol_name":"安聯環球可持續基金Cl AM Dis","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215621/0/en/ALK-to-present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference-in-San-Francisco.html","article_id":"2602391930","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602391930","pubTimestamp":1767889020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"ALK  today announced that the company’s president & CEO, Peter Halling, is scheduled to give a company presentation at the 44thAnnual J.P. Morgan Healthcare Conferencein San Franciscoon Thursday, 15 January 2026, at 9.45 AM PST / 12.45 PM EST / 6.45 PM CET. Representatives of the company will be available for meetings at the conference. ALK-Abelló A/S For further information, please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 Business Development: Rasmus Just, tel. +45 4171 8431 About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy  treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hrsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","XLV":"健康照护类股ETF-SPDR","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4581":"高盛持仓","LU1548497426.USD":"安联环球人工智能AT Acc","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0971096721.USD":"富达环球金融服务 A","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","HCSG":"Healthcare Svcs Group Inc","BK4500":"航空公司","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4534":"瑞士信贷持仓","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","BK4127":"投资银行业与经纪业","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4516":"特朗普概念","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4504":"桥水持仓","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","XBI":"SPDR S&P Biotech ETF","BK4008":"航空公司","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","BK4588":"碎股","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","ALK":"阿拉斯加航空集团有限公司","LABU":"三倍做多标普生物-Direxion","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4137":"综合支持服务","LU0557290698.USD":"施罗德环球可持续增长基金","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC"},"translate_title":"ALK将出席在旧金山举行的第44届摩根大通医疗保健年会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"HCSG":1.5,"ALK":1.5,"LABU":0.6,"XLV":1.5},"content_text":"ALK (ALKB:DC / OMX: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to give a company presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, 15 January 2026, at 9.45 AM PST / 12.45 PM EST / 6.45 PM CET. Representatives of the company will be available for meetings at the conference. ALK-Abelló A/S For further information, please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 Business Development: Rasmus Just, tel. +45 4171 8431 About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net. \nAttachment\n\n\n\nInvestorNews_08January26_JP Morgan Global Healthcare Conference","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}